Elucidation of shorten mechanism and detection of mutations for circulating tumor DNA in renal cell carcinoma patients.
| Project/Area Number |
18K16692
|
|---|
| Research Category |
Grant-in-Aid for Early-Career Scientists
|
| Allocation Type | Multi-year Fund |
|---|
| Review Section |
Basic Section 56030:Urology-related
|
|---|
| Research Institution | Osaka University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2018-04-01 – 2020-03-31
|
| Project Status |
Completed (Fiscal Year 2019)
|
| Budget Amount *help |
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2019: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2018: ¥2,470,000 (Direct Cost: ¥1,900,000、Indirect Cost: ¥570,000)
|
|---|
| Keywords | 腎癌 / 循環腫瘍DNA / 血中遊離DNA / バイオマーカー |
|---|
| Outline of Final Research Achievements |
Renal cell carcinoma has genetic heterogeneity, and blood biomarkers which can overcome this problem are needed. Generally, blood examinations are relatively minimum invasive, and can be performed repeatedly. Recently, plasma cell free DNA attracts attention as a resource of liquid biopsy. In this study, we focused on circulating tumor DNA which was cell free DNA derived from cancer cells. We developed genetic examination of circulating tumor DNA specific to renal cell carcinoma. The outcome through this study can contribute to improvement of medical care for renal cell carcinoma.
|
| Academic Significance and Societal Importance of the Research Achievements |
腎癌は典型的な不均一性を持つ癌腫であり、それを克服する血液バイオマーカーが求められている。血液採取は比較的低侵襲でかつ複数回採取が可能であり、病勢モニタリングにより最適なリソースである。近年、血中遊離DNAがliquid biopsyとして注目されている。本研究では血中遊離DNAの中でも、特に癌細胞由来である循環腫瘍DNAに着目した。本研究で同定した循環腫瘍DNAの臨床応用が期待され、患者への負担、医療費の削減を含めた社会への貢献の意義は大きいと考えている。
|
Report
(3 results)
Research Products
(3 results)
